The Importance of End-to-End Quality Control Processes for RNA Biomarker Discovery

Next-generation RNA sequencing unlocks the discovery of novel candidate biomarkers for diagnostic and therapeutic applications, but reproducibility is a key challenge in biomarker discovery programs. Integrating multifaceted quality control (QC) steps can improve design decisions and enhance the confidence and reliability of results. This webinar will demonstrate how a comprehensive QC framework supports a disease-agnostic biomarker discovery program to identify biologically relevant candidate biomarkers of complex disease. It will also highlight how this framework can be adapted for total RNA sequencing of whole blood, plasma, and serum samples.

Key learning objectives

• Learn how RNA sequencing enables the discovery of novel candidate biomarkers
• Discover how comprehensive sample QC framework allows to identify the biologically relevant candidate biomarkers
• Understand how Agilent TapeStation systems enable reliable QC in RNA sequencing workflows

Who should attend?

• NGS and genomics researchers
• Molecular biologists
• Cancer researchers
• Sequencing lab managers and technicians

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.